Michael Aguiar - Theravance Insider

THRX -- USA Stock  

null 9.81  9.81  9,223,372,036,855%

Mr. Michael W. Aguiar serves as President Chief Executive Officer Director of Theravance Inc. effective August 15 2014. He was appointed President and Chief Executive Officer of Innoviva Inc. and became a member of our Board of Directors in August 2014. He joined Innoviva as Senior Vice President and Chief Financial Officer in March 2005. Prior to joining Innoviva Mr. Aguiar served as Vice President of Finance at Gilead Sciences Inc. a biopharmaceutical company since 2002. Prior to Gilead Sciences Inc. Mr. Aguiar served as Vice President of Finance at Immunex Corporationrationration a biopharmaceutical company from 2001 to 2002. From 1995 to 2001 he was with Honeywell International in a variety of positions including most recently CFO and Vice President Finance for Honeywell Electronic Materials SBU. Mr. Aguiar earned a B.S. in biology from the University of California Irvine and an M.B.A. in finance from the University of Michigan. Mr. Aguiar demonstrated leadership in his field his prior senior management experience in our industry and his experience as our Chief Executive Officer and as our former Chief Financial Officer contributed to our conclusion that he should serve as a director.
Age: 48  CEO Since 2014  MBA    
650-238-9600  http://www.thrxinc.com
Aguiar earned a B.S. in Biology from UC Irvine and an M.B.A. in Finance from the University of Michigan.

Michael Aguiar Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 1.82 % which means that it generated profit of $1.82 on every $100 spent on asset. This is way below average.
The company currently holds 744.09 M in liabilities with Debt to Equity (D/E) ratio of 1.09 which is about average as compared to similar companies. Theravance has Current Ratio of 19.44 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 1 records

CEO Since

Jose LimMetro Pacific Investments Corpo

Entity Summary

Theravance, Inc., a royalty management company, is focused on developing respiratory products. Theravance (THRX) is traded on NASDAQ in USA. It is located in South San Francisco, CA and employs 13 people.

Theravance Leadership Team

Catherine Friedman, Independent Director
Michael Aguiar, CEO and President and Director
Barbara Duncan, Independent Director
Paul Pepe, Independent Director
George Abercrombie, Senior Vice President - Corporate Partnerships, Commercial
Patrick LePore, Independent Director
James Tyree, Independent Director
Eric dEsparbes, CFO and Sr. VP
Terrence Kearney, Independent Director
Michael Faerm, Chief Bus. Officer and Sr. VP
Theodore Witek, Sr. VP of Corporate Partnerships, Clinical and Medical Affairs
William Waltrip, Lead Independent Director

Stock Performance Indicators

Current Sentiment - THRX

Theravance Investor Sentiment

Most of Macroaxis users are at this time bullish on Theravance. What is your outlook on investing in Theravance? Are you bullish or bearish?
98% Bullish
2% Bearish
Currently Active Assets on Macroaxis
Purchased a lot of shares of
a day ago
Traded for 156.0
Purchased a lot of shares of
a day ago
Traded for 156.0
Purchased over 300 shares of
a day ago
Traded for 9.81
Purchased over 40 shares of
a day ago
Traded for 74.735
Purchased over 70 shares of
a day ago
Traded for 36.08
Also please take a look at World Market Map. Please also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Search macroaxis.com